Evaluation of Lamivudine Resistance Assay Using a Molecular Method in Patients with Chronic Hepatitis B

Objective: Lamivudine is a nucleoside analogue approved by the FDA in 1998 for the treatment of chronic hepatitis B. Its unique disadvantage compared to other antiviral agents used in hepatitis B treatment is the emergence of drug resistance during treatment. In this study, we aimed to determine lam...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Viral Hepatit Dergisi 2015-04, Vol.21 (1), p.17-19
Hauptverfasser:	KÖSE, Şükran, TÜRKEN, Melda, GÜL, Selma
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral drugs Drug resistance Hepatitis Mutation Pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!